Physician profile
Alexandria Adele Sanchez
NPI 1205281102
$1,108.10
in general payments reported to CMS, 2019-2025
21 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $154 · 2023: $251 · 2024: $220 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $192.72 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Abbvie INC. | $153.98 | 2024-2025 | |
| Exact Sciences Corporation | $132.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $96.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $80.72 | 2023-2024 | Perclose Proglide, Freestyle Libre 3 |
| Pfizer INC. | $50.77 | 2022-2025 | |
| Braeburn INC. | $50.34 | 2025 | Brixadi |
| Lilly USA, LLC | $49.30 | 2024 | Zepbound, Mounjaro |
| Renalytix Ai, INC. | $36.99 | 2022 | |
| Edwards Lifesciences Corporation | $33.48 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $31.98 | 2024-2025 | Quviviq, Quviviq |
| Otsuka America Pharmaceutical, INC. | $26.53 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $24.20 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.60 | 2025 | Caplyta |
| Indivior INC. | $22.54 | 2025 | Sublocade |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.64 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2023 | |
| Astellas Pharma US INC | $16.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.13 | 2023 | Andexxa |
| Amgen INC. | $13.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandria Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.